MedTrace Logo

The Impact of Salmon Protein Hydrolysate (SPH / ProGo®) Supplementation on Hematologic and Metabolic Health

NCT07616752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-06-01

No results posted yet for this study

Summary

Healthy, overweight males and females randomised to receive 8-weeks of salmon protein hydrolysate SPH (12g daily) or whey protein isolate (12g daily) to assess the impact on red blood cell and ferritin levels, blood glucose levels, BMI, percent body fat and lean body mass along with hair, skin and nail health and blood biomarkers of inflammation.

Conditions

Interventions

OTHER

Nutritional supplementation

ProGo is a proprietary mix of bioactive peptides.

OTHER

Nutritional Supplement

Standard whey protein

Sponsors & Collaborators

  • Hofseth Biocare ASA

    lead INDUSTRY

Principal Investigators

  • Freddy Halvadar, PhD · GPH Biotech LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-19
Primary Completion
2019-11-03
Completion
2020-01-03

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07616752 on ClinicalTrials.gov